Literature DB >> 28890077

Occlusion dose monitoring in amblyopia therapy: status, insights, and future directions.

Catherine E Stewart1, Merrick J Moseley2, Pantelis Georgiou3, Alistair R Fielder2.   

Abstract

Occlusion therapy remains the mainstay treatment of amblyopia, but its outcome is not assured or universally excellent. Many factors are known to influence treatment outcome, among which compliance is foremost. The occlusion dose monitor (ODM) removes one variable from the treatment equation, because it records the occlusion actually received by-rather than prescribed for-the child. Improvement observed can thus be quantitatively related to the patching received. This review summarizes the insights the ODM has provided to date particularly in elucidating the dose-response relationship. We are entering the era of personalized ophthalmology in which treatments will be tailored to the needs of the individual child and facilitated by the use of wearable monitors.
Copyright © 2017 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28890077     DOI: 10.1016/j.jaapos.2017.06.018

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  5 in total

1.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Riaz Qureshi; Kate Taylor
Journal:  Cochrane Database Syst Rev       Date:  2019-08-28

2.  Measuring aniseikonia and investigating neuroplasticity and image factors in amblyopia (MAGNIFY): study protocol for a randomised clinical trial.

Authors:  Jayshree South; Tina Gao; Melinda Calderwood; Jason Turuwhenua; Paul Roberts; Arier Lee; Andrew Collins; Joanna Black
Journal:  Trials       Date:  2022-04-27       Impact factor: 2.728

3.  Improved monitoring of adherence with patching treatment using a microsensor and Eye Patch Assistant.

Authors:  Jingyun Wang; Hongxin Xu; Bryan De La Cruz; Sarah E Morale; Reed M Jost; David A Leske; Jonathan M Holmes; Eileen E Birch
Journal:  J AAPOS       Date:  2020-03-18       Impact factor: 1.220

Review 4.  Active Vision Therapy for Anisometropic Amblyopia in Children: A Systematic Review.

Authors:  Carlos J Hernández-Rodríguez; David P Piñero
Journal:  J Ophthalmol       Date:  2020-03-23       Impact factor: 1.909

5.  Efficacy of vision therapy for unilateral refractive amblyopia in children aged 7-10 years.

Authors:  Yi-Ching Hsieh; Wen-Ling Liao; Yi-Yu Tsai; Hui-Ju Lin
Journal:  BMC Ophthalmol       Date:  2022-01-31       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.